Bing Center for Waldenstrom's Macroglobulinemia

Completed Trials

The clinical trials listed below have been completed and are closed to enrollment:

Title
Rituximab plus Fludarabine for patients with WM
Phase-2: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Phase II Study of VELCADE (PS-341) in WM
Phase II Study of Thalidomide and Rituximab for patients with WM
Phase II Study of Simvastatin in WM
Phase II Study of Perifosine in Patients with Relapsed/Refractory WM
Phase II Study of Imatinib Mesylate (Gleevec) in Relapsed or Refractory WM
Phase II Study of Combination Therapy with bortezomib and rituximab in patients with relapsed/refractory Waldenstrom’s macroglobulinemia.
Phase II Study of CC-5013 (Lenalidomide , Revlimid(tm)) and rituximab in Waldenstrom's macroglobulinemia
Phase II Clinical Trial of Sildenafil Citrate in WM
Phase II Clinical Trial of RAD001 in relapsed/refractory lymphoma
Phase II Clinical Trial of combination therapy with bortezomib, dexamethasone, and rituximab in patients with WM
Extended Rituximab for patients with WM
Campath-1H for patients with relapsed and refractory WM
An Open Label, Multicenter Phase-2 Study of Single-Agent Enzastaurin HCl in Previously Treaed Waldenstrom's Macroglobulinemia or Multiple Myeloma